JLE

Journal de Pharmacie Clinique

MENU

Cost evaluation of high dose chemo-radiotherapy in small cell lung cancer Volume 18, issue 1, Mars 1999

Figures

See all figures

Authors

A phase II clinical trial evaluates the benefit of combined high chemo-radiotherapy for patients suffering from limited small cell lung cancer limited. The aim of our study is to determine the mean total cost of fours intensive chemotherapy cycles. Our analysis includes chemotherapy and adjuvant medications e.g. antibiotics, haematopoietic factors, antiemetic drugs), thoracic radiotherapy, prophylactic cranial irradiation, autologous bone marrow transplantation and paraclinical exams. These preliminary results show that medications’ costs are the most important ones (53 %). Elsewhere, in spite of the best supportive care, haematologic complications increases the duration of hospitalisation as compared to conventional chemotherapy. A cost effectiveness prospective study associated with a quality of life questionnary is warranted in order to improve the « pharmaceutical management » of such new therapeutic strategies.